ERBB2 and ovarian cancer: In vivo testing on ovarian cancer-bearing mice revealed that [68Ga]Ga-(HE)3DANS-ADAPT6-GSSC-NODAGA achieved the best TBR (compared to DOTA, DOTAGA, and NOTA variants), highlighting its potential as a promising small molecule for HER2 targeting [84].